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Abstract
Background:  Neurocognitive impairment and psychiatric symptoms have been associated with deficits in
psychosocial and occupational functioning in patients with schizophrenia. This post-hoc analysis evaluates the
relationships among cognition, psychopathology, and psychosocial functioning in patients with schizophrenia at
baseline and following sustained treatment with antipsychotic drugs.
Methods: Data were obtained from a clinical trial assessing the cognitive effects of selected antipsychotic drugs
in patients with schizophrenia. Patients were randomly assigned to 24 weeks of treatment with olanzapine (n =
159), risperidone (n = 158), or haloperidol (n = 97). Psychosocial functioning was assessed with the Heinrichs-
Carpenter Quality of Life Scale [QLS], cognition with a standard battery of neurocognitive tests; and psychiatric
symptoms with the Positive and Negative Syndrome Scale [PANSS]. A path-analytic approach was used to
evaluate the effects of changes in cognitive functioning on subdomains of quality of life, and to determine whether
such effects were direct or mediated via changes in psychiatric symptoms.
Results: At baseline, processing speed affected functioning mainly indirectly via negative symptoms. Positive
symptoms also affected functioning at baseline although independent of cognition. At 24 weeks, changes in
processing speed affected changes in functioning both directly and indirectly via PANSS negative subscale scores.
Positive symptoms no longer contributed to the path-analytic models. Although a consistent relationship was
observed between processing speed and the 3 functional domains, variation existed as to whether the paths were
direct and/or indirect. Working memory and verbal memory did not significantly contribute to any of the path-
analytic models studied.
Conclusion: Processing speed demonstrated direct and indirect effects via negative symptoms on three domains
of functioning as measured by the QLS at baseline and following 24 weeks of antipsychotic treatment.
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Background
Neurocognitive impairment has been found to be
strongly correlated with deficits in psychosocial and occu-
pational functioning in patients with schizophrenia [1,2].
These earlier reviews of the literature (including a meta-
analysis) were focused on identifying specific neurocogni-
tive deficits that restrict the functioning of schizophrenia
patients, as opposed to the use of more global measures of
neurocognitive functioning such as IQ. The results sug-
gested associations between community functioning and
verbal memory, card sorting/executive function, and ver-
bal fluency, and associations between social problem-
solving skills and vigilance and secondary verbal memory.
Since these earlier reviews, a substantial body of research
has confirmed and extended these observations.
Psychiatric symptoms have also been associated with
functional impairment with early studies reporting the
most consistent or strongest association for negative
symptoms [3-5]. A substantial body of literature has since
accumulated addressing, in part, the relative strength of
associations of psychopathology and neurocognition
with functional outcomes, with some studies reporting a
greater effect of psychiatric symptoms on functioning
[6,7], others concluding a greater role of neurocognition
[1,8], and still others showing an important role of both
[9-12]. The complexity among these findings, and in this
area of research in general, likely reflects a number of
moderating variables including patients' chronicity of ill-
ness, acute exacerbation versus more residual (stable)
symptoms, overall symptom profile, study design (i.e.,
cross-sectional vs. longitudinal, inpatient/outpatient),
and perhaps variability and redundancy across the pleth-
ora of psychometric tests (and component factor analy-
ses) used to assess neurocognition, symptoms and
functioning. Additional research is needed to understand
how neurocognition and psychiatric symptoms can influ-
ence functional outcomes given the observed complexi-
ties and with the important goal of identifying those
factors that can enhance patients' psychosocial and occu-
pational functioning.
Several path-analytic studies have been conducted to eval-
uate the causal relationships among neurocognition, psy-
chiatric symptoms, and functioning [8,13-15]. Velligan
and colleagues reported a path model in which cognition
predicted both concurrent symptomatology and activities
of daily living while symptoms had little direct impact
upon activities of daily living [8]. In patients switched
from one antipsychotic to another (ziprasidone), Harvey
presented a path analysis showing that improvement on
the PANSS cognitive subscale directly affected changes on
the PANSS anxiety-depression cluster and a "PANSS
prosocial" subscale composed of items related to social
engagement, while improvement on the PANSS anxiety-
depression cluster had a direct effect on PANSS prosocial
subscale [13]. Bowie and colleagues utilizing a composite
score of neurocognition [14] reported that neuropsycho-
logical performance predicted functional capacity, which
predicted three domains of real-world functioning (i.e.,
interpersonal skills, work skills, and community activi-
ties). In addition, depression predicted interpersonal and
work skills, while negative symptoms affected interper-
sonal skills. Subsequently, Bowie and colleagues utilizing
specific neuropsychological measures [15] reported that
four cognitive factors (i.e., attention/working memory,
processing speed, verbal memory and executive function-
ing) demonstrated both direct and indirect effects via
functional competence and/or social competence on real
world outcomes. Symptoms (positive, negative and
depression) were directly related to outcomes, with fewer
indirect relationships associated with the competence fac-
tors. Most of these studies suggest a role for both neuro-
cognition and symptoms in mediating functional
outcomes, although the models differ somewhat in the
proposed relationship among the variables. Moreover,
with the exception of the Bowie et al. article [15], most of
these studies utilized composite measures to assess cogni-
tive abilities and/or functioning.
Two recent studies assessed the magnitude of associations
of psychiatric symptoms and neurocognition with the
Heinrich's Quality of Life Scale (QLS) [11.12]. In the cur-
rent study, we were interested in addressing potential
causal relationships among specific neurocognitive
domains – working memory, verbal memory, and
processing speed, and discrete domains of functioning of
the QLS – instrumental, intrapsychic, and interpersonal,
at baseline and following 24 weeks of antipsychotic drug
treatment in patients with schizophrenia. We used a path
analytic approach to evaluate both the direct effects of
neurocognitive domains on various aspects of patients'
functioning, as well as the indirect effects of such
domains, as mediated via changes in psychiatric symp-
toms. We were interested in evaluating these relationships
prior to treatment and after treatment.
Methods
Subjects
Patients were enrolled in a 1-year, double-blind, rand-
omized study of the neurocognitive efficacy of olanzapine
[OLZ], risperidone [RIS], and haloperidol [HAL] in the
treatment of schizophrenia [16]. Enrollment criteria
included: patients 18 to 55 years of age who met the crite-
ria for schizophrenia or schizoaffective disorder as
defined by the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition [DSM-IV]. Patients (N = 414)
were randomly assigned (1:1:1 ratio) to 52 weeks of treat-
ment with OLZ (N = 159; 5 to 20 mg/day), RIS (N = 158;
2 to 10 mg/day), or HAL (N = 97; 2 to 19 mg/day). During
the initial 8 weeks, a flexible dosing schedule was allowed;
thereafter a fixed dose based on investigator's judgmentBMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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was suggested. In this analysis, patients from all 3 treat-
ment groups were included. As noted in the original
report, the mean modal dose was 12.3 mg/day for olanza-
pine, 5.2 mg/day for risperidone, and 8.2 mg/day for
haloperidol among patients who completed the study
[16].
Variables Assessed
Functioning was assessed with the Heinrichs-Carpenter
Quality of Life Scale [QLS] [17]; we focused on 3 of the 4
subdomains of functioning. The first subdomain used was
the Instrumental Role Functioning [QLS Instrumental],
which measures the level of, and satisfaction with, occu-
pational role functioning. We averaged the following 4
items: extent of occupational role functioning, level of
accomplishment, degree of underemployment, and satis-
faction with occupational role functioning. The second
subdomain used was the Intrapsychic Foundation [QLS
Intrapsychic], which measures variables related to sense of
purpose, motivation, and empathy. We averaged the fol-
lowing 7 items: sense of purpose, degree of motivation,
curiosity, anhedonia, time utilization, capacity for empa-
thy, and capacity for engagement and interaction. The
final subdomain used was the Interpersonal Relations
[QLS Interpersonal], which measures the qualitative
aspects of interpersonal relationships. We averaged the
following 8 items: interpersonal relationship with house-
hold members, intimate relationships, active acquaint-
ances, level of social activity, involved social network,
social initiatives, and social withdrawal socio-sexual rela-
tions.
Psychiatric symptoms were assessed using the Positive
and Negative Syndrome Scale [PANSS] [18]. This analysis
focused on the PANSS overall score, and negative and pos-
itive subscale scores: PANSS overall = mean of 30 items
[score of each item ranging from 1 (least severe) to 7
(most severe)], PANSS negative subscale [PANSS Neg] =
mean of 7 items (#8, 9, 10, 11, 13, 21, 30), PANSS posi-
tive subscale [PANSS Pos] = mean of 8 items (#1, 3, 5, 6,
14, 15, 23, 26).
Patients were assessed with a comprehensive battery of
neurocognitive tests [16]. We selected measures represent-
ing 3 major domains of cognition that we considered may
be relevant as predictors of functional outcomes. As a sen-
sitivity check, we considered incorporating a fourth
"problem solving" or "executive" domain. In the presence
of other cognitive variables, however, it did not add value
in modeling changes in functional outcomes (via direct or
indirect effects).
Cognitive variables were transformed into z-scores against
healthy controls for 3 main areas of cognition: 1) working
memory, as assessed by the Letter-Number Sequencing
verbal subtest of the Wechsler Adult Intelligence Scale,
Third Edition [WAIS-III]; 2) verbal memory, as assessed
by the Rey Auditory-Verbal Learning Test with Crawford
Alternative (10 minute); and 3) processing speed, com-
puted as an average of the following 2 subscales: a)
processing speed (digit-symbol coding), as assessed by the
WAIS-R Digit-Symbol Coding performance subtest, and
b) verbal fluency scale, constructed as an average of Cate-
gory Instances and Controlled Oral Association Test.
Although digit-symbol and verbal fluency are complex
tasks that draw on a variety of cognitive processes, we fol-
lowed the conceptualization of the MATRICS group, who
placed verbal fluency and digit-symbol together in the
same domain of "processing speed" based upon their
review of several factor analyses available at the time [19].
Data from the Grooved Pegboard Tests were excluded
from assessment of processing speed because of a large
number of unusually high values.
Statistical Methodology
Separate path-analytic models were evaluated for: 1) the 3
subdomains of functioning from the QLS – QLS Instru-
mental, QLS Intrapsychic, and QLS Interpersonal, and 2)
relationships among pretreatment (baseline) measures
and for changes in these measures to the 24-week end-
point. Therefore, a total of 6 models were constructed.
Endpoint was defined as last observation prior to, or at, 24
weeks. We used a 24-week endpoint as significant changes
were observed in both cognitive and functional measures
at this time, and a substantial reduction in sample size
had occurred by the next scheduled assessment (52
weeks).
In modeling these relationships, our fundamental
assumption was that cognitive impairment precedes psy-
chiatric symptoms, and that both precede functional
impairment as the illness of schizophrenia evolves in
patients. Therefore, we hypothesized that cognitive status
at baseline and subsequent changes in cognition could
predict functioning either directly or indirectly via psychi-
atric symptoms (Figure 1), but not the other way around
(e.g. changes in psychiatric symptoms affecting function-
ing via changes in cognition). Considering the various
domains of psychopathology, we also hypothesized that
negative symptoms would most strongly mediate the
effects of cognition on functioning.
Each model incorporated the following: 1) 3 measures of
cognition, including working memory, processing speed,
and verbal memory as the independent variables; 2)
PANSS Neg and PANSS Pos as intermediate outcomes;
and 3) 1 of 3 functional domains, including QLS Instru-
mental, QLS Intrapsychic, and QLS Interpersonal as the
dependent (outcome) measure.
For each outcome, we started with a model that was close
to saturated and then excluded pathways that were notBMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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statistically significant and did not contribute to the over-
all model fit as measured by 3 criteria: 1) chi-squared sta-
tistics for the goodness of fit and associated p-value
(significant p-value indicating poor fit); 2) Comparative
Fit Index [CFI] (ranging from 0 to 1, higher values indicat-
ing better fit); and 3) Root Mean Square Error of Approx-
imation [RMSEA]. An RMSEA of 0.05 or less indicates a
good fit and an RMSEA of 0.10 or more indicates a poor
fit.
Analyses were conducted using SAS® Version 8 for PC.
Path-analytic models were evaluated using SAS PROC
CALIS.
Results
Patient Characteristics
The baseline values for all measures included in this anal-
ysis can be found in Table 1. The majority of patients were
male with an average age of approximately 39 years of age.
The average age of onset of the disease was approximately
23.1 years of age, with a mean number of 7 episodes.
Averaged scores are provided for all of the scales assessed.
Changes in Cognitive Measures and Functioning from 
Baseline to Week 24
Changes in cognitive measures and functioning from
baseline are provided in Figure 2. For cognition, signifi-
cant improvement from baseline was observed in working
memory and verbal memory, although not in processing
speed. For functioning, significant improvement from
baseline was observed for the QLS Instrumental and QLS
Intrapsychic subdomains, but not for the QLS Interper-
sonal subdomain.
Path Analysis for Cognition, Symptoms, and Functioning at 
Baseline
Pairwise correlations for measures at baseline are shown
in Table 2. Inspection of these raw correlations suggests
that selected cognitive measures and symptoms are highly
correlated with certain domains of functioning. The direct
and indirect relationships observed among cognition,
symptoms and the three subdomains of functioning at
baseline are illustrated in the path analytic diagrams pre-
sented in Figure 3.
At baseline, processing speed affected functioning mainly
indirectly via negative symptoms (PANSS Neg); patients
who had faster processing speed had fewer negative symp-
toms and better overall functioning. Working memory
and verbal memory did not significantly contribute to the
path-analytic models at baseline. Positive symptoms
(PANSS Pos) also contributed to the patient's functional
status at baseline, independent of cognition.
Path Analysis for Changes in Cognition, Symptoms, and 
Functioning at 24-Week Endpoint
Pairwise correlations between changes in all measures at
endpoint (Week 24) are shown in Table 3. Interestingly,
In constructing path models, our fundamental assumption was that cognitive impairment precedes psychiatric symptoms and  both precede functional impairment; therefore, cognitive status at baseline and changes in cognition may affect functioning  either directly or indirectly via psychiatric symptoms Figure 1
In constructing path models, our fundamental assumption was that cognitive impairment precedes psychiatric 
symptoms and both precede functional impairment; therefore, cognitive status at baseline and changes in cog-
nition may affect functioning either directly or indirectly via psychiatric symptoms.BMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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these correlations were more moderate compared with
those at baseline. Among cognitive measures, only
changes in processing speed were significantly related to
changes in functioning. Among symptoms, only changes
in negative symptoms were significantly associated with
changes in functioning. The path-analytic diagrams for
the relationships among cognition, symptoms, and the 3
subdomains of functioning at 24 weeks are shown in Fig-
ure 4.
At 24 weeks, changes in processing speed affected changes
in functioning, both directly and indirectly via changes in
negative symptoms (PANSS Neg). Changes in working
memory and verbal memory did not significantly contrib-
ute to the path-analytic models at 24 weeks. Changes in
positive symptoms (PANSS Pos) were not significantly
associated with changes in any of the 3 functional
domains.
Discussion
In this study, we evaluated the interaction among 3 neu-
rocognitive domains (i.e., working memory, verbal mem-
ory, and processing speed) and 3 discrete domains of
functioning (i.e., QLS Instrumental, QLS Intrapsychic,
and QLS Interpersonal) at baseline and following 24
weeks of antipsychotic drug therapy in patients with
schizophrenia. In our path-analytic models, we also incor-
porated positive and negative symptoms to assess whether
cognitive variables may directly or indirectly affect func-
tioning; in the latter case, via changes in symptoms. We
found that only processing speed was significantly associ-
ated with functioning at both baseline and at 24 weeks.
Processing speed affected functioning both directly and
indirectly via negative symptoms, although the partition-
ing of the total effect into direct and indirect parts varied
somewhat for each domain of functioning assessed,
including QLS Instrumental (work), QLS Intrapsychic,
and QLS Interpersonal (psychosocial) domains. In addi-
Table 1: Baseline characteristics.
Demographics N = 395*
Gender (% females) 28.9%
Age, years; mean (SD) 39.1 (8.2)
Age at onset of disease, years; mean (SD) 23.1 (7.1)
Severity of Psychopathology
Previous number of episodes; mean (SD) 6.65 (8.3)
PANSS overall score; mean (SD) 2.76 (0.46)
PANSS negative; mean (SD) 2.83 (0.81)
PANSS positive; mean (SD) 3.18 (0.66)
Quality of Life Functional Domains
QLS Instrumental Role Functioning; mean (SD) 3.35 (0.90)
QLS Interpersonal Relations; mean (SD) 2.57 (1.16)
QLS Intrapsychic Foundation; mean (SD) 2.99 (1.13)
Cognitive Subdomains (z scores against healthy controls)
Working Memory; mean (SD) -1.01 (1.12)
Verbal Memory; mean (SD) -1.41 (1.3)
Processing Speed; mean (SD) -1.12 (0.80)
*Number based on patients with non-missing values for scales assessed.BMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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Changes in cognitive measures and functioning from baseline to Week 24 Figure 2
Changes in cognitive measures and functioning from baseline to Week 24.
Table 2: Pairwise Pearson correlations for measures at baseline (N = 395).
QLS 
Intrapsychic
QLS 
Intpersonal
Processing 
Speed
Working 
Memory
Verbal Memory Neg Pos PANSS Overall
QLS 
Instrumental
0.58*** 0.47*** 0.15** 0.13** 0.16** -0.23*** -0.22*** -0.32***
QLS 
Intrapsychic
0.64*** 0.21*** 0.16** 0.15** -0.48*** -0.26*** -0.47***
QLS 
Interpersonal
0.15** 0.02 0.02 -0.38*** -0.26*** -0.37***
Processing 
Speed
0.55*** 0.53*** -0.16** -0.03 -0.08
Working 
Memory
0.48*** -0.02 -0.09 -0.10
Verbal Memory -0.07 -0.02 -0.11*
PANSS Neg 0.13* 0.61***
PANSS Pos 0.72***
*p < .05, **p < .01, ***p < .001BMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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Path diagram for relationships among cognition, symptoms, and occupational functioning at baseline for the 3 functional  domains Figure 3
Path diagram for relationships among cognition, symptoms, and occupational functioning at baseline for the 3 
functional domains: 1) QLS Instrumental, 2) QLS Intrapsychic, and 3) QLS Interpersonal. Values associated with directed 
pathways are standardized path coefficients; values over the double-arrowed arches are correlations; asterisks indicate statisti-
cal significance at *p < .05, **p < .01, ***p < .001. The pathways with z-scores less than 1.8 were not shown.BMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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tion, we found that positive symptoms also affected func-
tioning at baseline.
As reviewed by Bowie et al. [15], processing speed impair-
ments may reflect a core cognitive deficit in schizophre-
nia. In a recent meta-analytic study, Dickinson and
colleagues [20] reported that the digit-symbol coding task,
a measure of processing speed, represented the greatest
deficit among cognitive abilities in patients with schizo-
phrenia. Processing speed was also identified as the most
sensitive index in patients with schizophrenia for the
WAIS-III technical manual [21]. Processing speed, as
measured by the digit-symbol coding task, accounted for
65% of the variance in overall cognitive performance and
was the best single predictor of total score in the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE)
analyses [22]. Bowie and colleagues [15] found that the
processing speed factor, which included the digit-symbol
coding task, consistently predicted social competence and
living skills and was the only factor to have a direct effect
on all 3 real-world behaviors. It has been suggested that
slowed information processing (including slowed encod-
ing) can account for deficits in a range of higher level cog-
nitive functions in schizophrenia including deficits in
working memory, executive function and memory
[23,24].
In the current study, we focused on the digit-symbol cod-
ing task and verbal fluency as two measures of processing
speed. We were unable to utilize data from the Grooved
Pegboard Tests because there were a large number of unu-
sually high values. However, a recent review on psycho-
motor slowing in schizophrenia has suggested that
psychomotor slowing may be distinguishable from a
reduction in the speed of information processing
(reviewed in [25]). While a number of neurocognitive
processes that support motor control are likely involved
in psychomotor functioning, in fact some tasks may be
more sensitive to psychomotor speed while others are
more sensitive to the speed of information processing. In
this regard, the digit-symbol coding task would be more
sensitive to the speed of information processing while the
pegboard task would have been more sensitive to psycho-
motor speed.
Based on our proposed model, processing speed worked,
in part, through negative symptoms to impact function-
ing. As proposed by Green and Nuechterlein [26], it is
possible that the relationship between negative symptoms
and functioning may reflect the shared variance between
negative symptoms and neurocognition, or the stronger
association between neurocognition and functional out-
comes. There is some data to suggest that while cognitive
deficits appear to develop at an earlier age than negative
symptoms, some neurocognitive deficits may act as vul-
nerability factors for development of negative symptoms
(reviewed in [26]). However, negative symptoms typically
have shown relatively weak correlations to cognitive defi-
cits [26], a finding that suggests that while there is some
shared variance in predicting outcomes, negative symp-
Table 3: Pairwise Pearson correlations between measures for changes to Week 24 (N = 208).
QLS 
Intrapsychic
QLS 
Interpersonal
Processing 
Speed
Working 
Memory
Verbal Memory Neg Pos PANSS Overall
QLS 
Instrumental
0.33*** 0.23*** 0.17* 0.06 0.03 -0.16* -0.07 -0.14*
QLS 
Intrapsychic
0.46*** 0.22** 0.11 0.06 -0.38*** -0.02 -0.17*
QLS 
Interpersonal
0.04 -0.11 -0.01 -0.17* -0.09 -0.16*
Processing 
Speed
0.29*** 0.25*** -0.17* 0.06 -0.05
Working 
Memory
0.08 0.04 -0.02 0.04
Verbal Memory -0.15* 0.12 -0.05
PANSS Neg 0.12 0.60***
PANSS Pos 0.75***
*p < .05, **p < .01, ***p < .001BMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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Path diagram for relationships among changes in cognition, symptoms, and occupational functioning at 24 weeks for the 3 func- tional domains Figure 4
Path diagram for relationships among changes in cognition, symptoms, and occupational functioning at 24 
weeks for the 3 functional domains: 1) QLS Instrumental, 2) QLS Intrapsychic, and 3) QLS Interpersonal. Values associ-
ated with directed pathways are standardized path coefficients; values over the double-arrowed arches are correlations; aster-
isks indicate statistical significance at *p < .05, **p < .01, ***p < .001. The pathways with z-scores less than 1.8 were not shown.BMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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toms and neurocognitive deficits are relatively distinct
constructs. Thus, negative symptoms may also have a
direct impact on a patient's overall level of functioning.
It has also been proposed that the causal pathways from
negative symptoms to functional outcomes may be due to
a common neurocognitive intersection [26]. Does process-
ing speed possibly serve as a neurocognitive intersection between
negative symptoms and functioning? Hughes and colleagues
[27] reported that significant improvements in symptom
ratings over time in patients with chronic schizophrenia
did not predict improvements in any aspect of cognitive
functioning measured, except motor speed. Rodriguez-
Sanchez and colleagues [28] analyzed the relationship
between different cognitive tasks and clinical symptoms
in patients with first-episode schizophrenia and found
that negative symptoms were significantly associated with
performance on executive functions and motor coordina-
tion tasks, with a significant association of negative symp-
toms seen only for those executive functions requiring
speeded performance. They concluded that the widely
described relationship between negative symptoms and
executive impairments in schizophrenia appears to be
mediated by dysfunction in processing speed.
Some have argued that the Heinrichs-Carpenter QLS sub-
titled as "an instrument for rating the schizophrenia defi-
cit syndrome" provides a clinical assessment of negative
symptoms more than a subjective measure of a patient's
quality of life [29]. Although not without controversy
[30], we cannot exclude the possibility that the strong
support for negative symptoms as a mediator between
cognition and functioning may be somewhat unique to
the use of the QLS.
In contrast to the Bowie et al. study [15], our path-analytic
models did not suggest the presence of a significant rela-
tionship between working memory or verbal memory and
functioning. However, previous work has incorporated
additional constructs, such as social competence and
functional competence, which may mediate the effect of
other cognitive parameters, such as memory, on function-
ing [15,31].
The observation that positive symptoms affected func-
tioning at baseline, but not after 24 weeks of treatment,
was somewhat surprising. However, positive symptoms
can improve quite rapidly with antipsychotic medication,
and it is possible that the timing of improvement in posi-
tive symptoms may have occurred more quickly than
improvement in functioning. Negative symptoms at base-
line (and with change) appeared to play a more dominant
role in functional outcomes.
Our inability to detect a stronger relationship between
cognition and functioning may have been hindered by the
lack of substantial improvement in both functioning and
cognition observed during the 24-week time period that
was analyzed. Long-term data on cognition and function-
ing are needed to obtain better estimation of potential
direct and indirect effects of cognition on functioning of
patients with schizophrenia.
A large number of dropouts (especially when caused by
lack of symptom improvement) may have introduced bias
in evaluating associations among changes in symptoms,
cognition, and functioning at the 24-week endpoint. In
the original report, 95 (59.7%) olanzapine-, 104 (65.8%)
risperidone-, and 70 (72.2%) haloperidol-treated patients
had discontinued for any reason; out of these, 20 (12.6%)
olanzapine-, 18 (11.4%) risperidone-, and 16 (16.5%)
haloperidol-treated patients had discontinued the study
for lack of efficacy [16].
To evaluate whether dropouts could have biased the path
analytic models estimated from observed changes at 24-
week endpoint we performed a sensitivity analysis by
imputing missing outcomes for subjects who discontin-
ued prior to week 24 using a single imputation from a
posterior predictive distribution of missing values given
all the subjects' outcome data observed up to their drop-
out (with Bayesian regression for monotone missing data
in SAS PROC MI). The results (not reported here) were
qualitatively similar to those based on observed data at
week 24.
While the relationship among variables could vary by
treatment, analyzing the data separately by treatment
groups would result in small subgroups with limited
power to detect significant differences. In the original
study [16], at the 52-week endpoint, neurocognition had
significantly improved in each group, with no significant
differences observed between groups. Although differ-
ences were observed on what specific domains improved
in the three treatment arms, the lack of differences
observed across the treatment groups overall and discon-
tinuation of the haloperidol arm per protocol limit fur-
ther analysis of this important issue in the current study.
Lastly, some studies have suggested that the effects of neu-
rocognition are mediated primarily through social cogni-
tion and subsequently through social competence and
social support [15,31]. We did not have data in which to
assess the role of social cognition or other social variables
in functioning.
Conclusion
Processing speed demonstrated direct and indirect effects
via negative symptoms on three domains of functioning
as measured by the QLS at baseline and following 24
weeks of antipsychotic treatment. These results highlight
the importance of improvement in negative symptomsBMC Psychiatry 2009, 9:44 http://www.biomedcentral.com/1471-244X/9/44
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and cognition (particularly processing speed) for improv-
ing functional outcomes of patients with schizophrenia.
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